---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-035812"
form_type: "8-K"
ticker: "GNPX"
cik: "0001595248"
company_name: "Genprex, Inc."
filed_at: "2024-11-20T23:59:59+00:00"
generated_at: "2026-05-29T21:48:57.480715+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Genprex enters exclusive license with Univ of Michigan for Reqorsa in ALK+ lung cancer

## Summary
- License grants Genprex worldwide exclusive rights to University of Michigan patents for Reqorsa gene therapy combined with ALK-inhibitors for ALK-EML4 positive NSCLC.
- Preclinical data at AACR April 2024 showed Reqorsa induced apoptosis in alectinib-resistant EML4-ALK positive NSCLC cell lines.
- Researchers believe results support further clinical study of Reqorsa as an anti-ALK NSCLC treatment strategy.

## SEC filing metadata
- accession: 0001437749-24-035812
- form_type: 8-K
- ticker: GNPX
- cik: 0001595248
- company_name: Genprex, Inc.
- filed_at: 2024-11-20T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1595248/000143774924035812/0001437749-24-035812-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1595248/000143774924035812/gnpx20241119_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-035812
- JSON: https://secwatch.observer/filing/0001437749-24-035812.json
- Plain text: https://secwatch.observer/filing/0001437749-24-035812.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.